Literature DB >> 14715796

Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Chihiro Morishima1, Minjun Chung, Ka Wing Ng, Donald J Brambilla, David R Gretch.   

Abstract

The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14715796      PMCID： PMC321650          DOI： 10.1128/JCM.42.1.421-425.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  22 in total

1.  Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay.

Authors:  Eric Q Konnick; Maria Erali; Edward R Ashwood; David R Hillyard
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.

Authors:  Marcel Beld; Roel Sentjens; Sjoerd Rebers; Christine Weegink; Jan Weel; Cees Sol; René Boom
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum.

Authors:  Pascale Trimoulet; Philippe Halfon; Eric Pohier; Hacène Khiri; Geneviève Chêne; Hervé Fleury
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.

Authors:  J Mellor; A Hawkins; P Simmonds
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

5.  Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  A Erice; D Brambilla; J Bremer; J B Jackson; R Kokka; B Yen-Lieberman; R W Coombs
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus.

Authors:  Kenneth E Sherman; Susan D Rouster; Paul S Horn
Journal:  Clin Infect Dis       Date:  2002-07-22       Impact factor: 9.079

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice.

Authors:  Mitchell L Shiffman; Andrea Ferreira-Gonzalez; K Rajender Reddy; Richard K Sterling; Velimir A Luketic; R Todd Stravitz; Arun J Sanyal; Carleton T Garrett; Maria De Medina; Eugene R Schiff
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

10.  Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum.

Authors:  Jeffrey J Germer; Paul J Heimgartner; Duane M Ilstrup; W Scott Harmsen; Greg D Jenkins; Robin Patel
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948
View more
  15 in total

1.  Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs.

Authors:  Petr Pancoska; Zdenek Moravek; Ute M Moll
Journal:  Nucleic Acids Res       Date:  2004-08-27       Impact factor: 16.971

Review 2.  Biological and nanotechnological applications using interactions between ionic liquids and nucleic acids.

Authors:  Hisae Tateishi-Karimata; Naoki Sugimoto
Journal:  Biophys Rev       Date:  2018-04-23

3.  Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

Authors:  Neal D Freedman; Teresa M Curto; Karen L Lindsay; Elizabeth C Wright; Rashmi Sinha; James E Everhart
Journal:  Gastroenterology       Date:  2011-03-02       Impact factor: 22.682

4.  Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Authors:  Chihiro Morishima; Mitchell L Shiffman; Jules L Dienstag; Karen L Lindsay; Gyongyi Szabo; Gregory T Everson; Anna S Lok; Adrian M Di Bisceglie; Marc G Ghany; Deepa Naishadham; Timothy R Morgan; Elizabeth C Wright
Journal:  Am J Gastroenterol       Date:  2012-06-12       Impact factor: 10.864

5.  Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Authors:  Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Minjun C Apodaca; David R Gretch; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S F Lok; Jules L Dienstag; Marc G Ghany; Teresa M Curto
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

6.  Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus.

Authors:  M Fernanda Sábato; Mitchell L Shiffman; Michael R Langley; David S Wilkinson; Andrea Ferreira-Gonzalez
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

7.  Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.

Authors:  Christoph Sarrazin; Barbara C Gärtner; Dorothea Sizmann; Rainer Babiel; Ulrike Mihm; Wolf Peter Hofmann; Michael von Wagner; Stefan Zeuzem
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection.

Authors:  Mel Krajden; Rishma Shivji; Kingsley Gunadasa; Annie Mak; Gail McNabb; Michel Friesenhahn; David Hendricks; Lorraine Comanor
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

9.  Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA.

Authors:  Linda Cook; Ka-Wing Ng; Arthur Bagabag; Lawrence Corey; Keith R Jerome
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

10.  Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.